Evidence map›Paper›PMID 39710698›Full record

ArticleJournal of nanobiotechnology2024

A shielded cascade of targeted nanocarriers spanning multiple microenvironmental barriers for inflammatory disease therapy.

Fengyi Liu, Xu Wang, Mingxing Ren, Ping He, Yuzhou Li, Jing Cui, Sheng Yang

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fengyi Liu *College of Stomatology, Chongqing Medical University, 426#Songshibei Road, Yubei District, Chongqing, 401147, China.
Xu Wang *College of Stomatology, Chongqing Medical University, 426#Songshibei Road, Yubei District, Chongqing, 401147, China.
Mingxing RenCollege of Stomatology, Chongqing Medical University, 426#Songshibei Road, Yubei District, Chongqing, 401147, China.
Ping HeCollege of Stomatology, Chongqing Medical University, 426#Songshibei Road, Yubei District, Chongqing, 401147, China.
Yuzhou LiCollege of Stomatology, Chongqing Medical University, 426#Songshibei Road, Yubei District, Chongqing, 401147, China.
Jing CuiChongqing Medical University, Chongqing, China.
Sheng YangCollege of Stomatology, Chongqing Medical University, 426#Songshibei Road, Yubei District, Chongqing, 401147, China. 500283@cqmu.edu.cn.

Funding

China Postdoctoral Science Foundation 2022M720598CQMU Program for Youth Innovation in Future Medicine W0079National Natural Science Foundation of China 82301034National Natural Science Foundation of China U23A20447Natural Science Foundation of Chongqing Municipality CSTB2023NSCQ-BHX0072Natural Science Foundation of Chongqing Municipality cstc2021jcyj-jqX0028Project of Chongqing Medical University Graduate Tutor Team cqmudstd202203Special Grant for Chongqing Postdoctoral Research Project 2022CQBSHTB3029
6 · The paper itself

Abstract

backgroundThe multi-biological barriers present in the inflammatory microenvironment severely limit the targeted aggregation of anti-inflammatory drugs in the lesion area. However, conventional responsive drug carriers inevitably come into contact with several pro-responsive stimulatory mediators simultaneously, leading to premature drug release and loss of most therapeutic effects. Breaking through the multi-level barriers of the inflammatory microenvironment is essential to improve the enrichment and bioavailability of drugs.

resultsIn this study, we propose a novel two-stage structural strategy to build shielded cascades of targeted nanocarriers (FA-PTP@Que) through inflammatory mediators, using cascade structures to cross multiple environmental barriers. The cascade structure of FA-PTP@Que is responsive to inflammatory mediators and exhibits ideal pathological microenvironmental response and drug release properties. FA-PTP@Que has shown good macrophage regulation and anti-inflammatory effects by efficiently targeting macrophages, scavenging intracellular reactive oxygen species (ROS), and down-regulating the secretion of pro-inflammatory factors. Significantly, in mice with arthritis and colitis, FA-PTP@Que enriches and targets macrophages at the sites of arthritis and colitis, showing significant anti-inflammatory effects.

conclusionFA-PTP@Que combines active chemotaxis of nanocarriers to inflammatory tissues and active targeting of effector cells, acting precisely at each barrier level in different microenvironments by responding to inflammatory mediators and overcoming the multiple barriers in the inflammatory microenvironment. This innovative strategy can effectively break through various inflammatory microenvironments and has the potential application to other inflammatory diseases.

Indexed as

Anti-Inflammatory AgentsDrug CarriersInflammationMacrophagesNanoparticlesReactive Oxygen SpeciesAnimalsArthritisCellular MicroenvironmentColitisDrug Delivery SystemsDrug LiberationMaleMiceRAW 264.7 CellsAnti-Inflammatory AgentsDrug CarriersReactive Oxygen SpeciesMacrophageMicroenvironmental barriersPAMAM dendrimerReactive oxygen species (ROS)-responsive

Identifiers

PMID39710698
PMCPMC11665124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.